RESUMEN
OBJECTIVE AND DESIGN: Hydroxamic-and carboxylic-acid based matrix metalloproteinase inhibitors (MMPIs) were compared for their potency against various MMPs, pharmacodynamic properties and in vivo efficacy in a model of cartilage degeneration. MATERIALS AND METHODS: The MMPIs were evaluated for their ability to inhibit human MMPs using the quenched fluorescence assay. The ability of the MMPIs to inhibit the degeneration of the knee joint was evaluated in rats injected intraarticularly with iodoacetate. The amount of MMPI in the plasma and cartilage was determined using liquid chromatography/mass spectrometry/mass spectrometry (LC/ MS/MS). Plasma protein binding was measured by ultrafiltration and unbound MMPI was quantitated using HPLC. RESULTS: The hydroxamic acid based inhibitor PGE-3321996 and the carboxylic acids PGE-2909492 and PGE-6292544 were potent MMP-13 inhibitors, but only the hydroxamic acid PGE 3321996 demonstrated significant inhibition of knee degeneration in the rat iodoacetate model. Both of the carboxylic acids demonstrated superior pharmacokinetic properties and established much higher plasma concentrations than the hydroxamic acid. However, neither of the carboxylic acids was detectable in the cartilage, whereas, the hydroxamic acid was present in both the cartilage and the plasma. The carboxylic acid based MMPIs also demonstrated higher plasma protein binding (>99%) than the hydroxamic acid (79%). CONCLUSIONS: Carboxylic acid-based MMPIs were identified that had superior in vivo plasma exposure compared to a hydroxamic acid inhibitor but lacked in vivo efficacy in the rat iodoacetate model of cartilage degeneration. The lack of in vivo efficacy of the carboxylic acid based MMPIs were probably due to their lack of cartilage penetration which was related to their physicochemical properties.
Asunto(s)
Aminoácidos/farmacocinética , Aminoácidos/uso terapéutico , Ácidos Carboxílicos , Ácidos Hidroxámicos/farmacocinética , Ácidos Hidroxámicos/uso terapéutico , Inhibidores de la Metaloproteinasa de la Matriz , Osteoartritis/tratamiento farmacológico , Fenilalanina/análogos & derivados , Inhibidores de Proteasas , Sulfonamidas/farmacocinética , Sulfonamidas/uso terapéutico , Sulfonas/farmacocinética , Sulfonas/uso terapéutico , Aminoácidos/química , Animales , Ácidos Carboxílicos/química , Ácidos Carboxílicos/farmacocinética , Ácidos Carboxílicos/uso terapéutico , Cartílago/química , Cartílago/patología , Modelos Animales de Enfermedad , Humanos , Ácidos Hidroxámicos/química , Yodoacetatos/toxicidad , Articulación de la Rodilla/patología , Masculino , Estructura Molecular , Osteoartritis/inducido químicamente , Osteoartritis/patología , Fenilalanina/química , Fenilalanina/farmacocinética , Fenilalanina/uso terapéutico , Plasma/química , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacocinética , Inhibidores de Proteasas/uso terapéutico , Ratas , Ratas Sprague-Dawley , Sulfonamidas/química , Sulfonas/químicaRESUMEN
OBJECTIVE: To characterize the time course of aggrecan and type II collagen degradation in the rat iodoacetate model of cartilage degeneration in relationship to the temporal sequence that has been described in human osteoarthritis (OA). DESIGN: Rats were injected intra-articularly in one knee joint with iodoacetate and damage to the tibial plateau was assessed from digitized images captured using an image analyzer. The articular cartilage from the tibial plateau was harvested, extracted and glycosaminoglycan (GAG) content was measured using the dimethylmethylene blue (DMMB) assay. Cartilage aggrecan neoepitopes were detected in cartilage extracts by Western blotting using antibodies recognizing the aggrecanase-generated C-terminal neoepitope NITEGE (BC-13) and the MMP-generated C-terminal neoepitope DIPEN (BC-4). A type II collagen collagenase-generated neoepitope was detected in cartilage extracts by ELISA using the Col2-3/4Cshort antibody; denatured collagen was detected using the Col2-3/4m antibody. RESULTS: Degenerative joint changes and proteoglycan (GAG) loss progressed with time after iodoacetate injection. Western blotting of cartilage extracts of iodoacetate treated rats demonstrated an increase in both aggrecanase- and MMP-generated epitopes with the NITEGE aggrecanase neoepitope being significantly elevated on days 7, 14 and 21 while DIPEN the MMP neoepitope was significantly elevated on days 7 and 14. The type II collagen neoepitope recognized by Col2-3/4Cshort was significantly increased in cartilage extracts of rats at days 14 and 21 after iodoacetate injection. CONCLUSION: The proteoglycan fragments extracted from the knee cartilage of rats after the intra-articular injection of iodoacetate appeared to result from cleavage at both aggrecanase and MMP sites. Cleavage of type II collagen by collagenase was also detected after iodoacetate injection and occurred subsequent to the initiation of aggrecan loss. These observations serve to demonstrate similarities in the mechanisms of cartilage degeneration induced by iodoacetate to those seen in articular cartilage in OA.
Asunto(s)
Cartílago Articular/metabolismo , Colágeno Tipo II/análisis , Endopeptidasas/metabolismo , Epítopos/análisis , Metaloproteinasas de la Matriz/metabolismo , Osteoartritis/metabolismo , Agrecanos , Animales , Colágeno/análisis , Colágeno/metabolismo , Proteínas de la Matriz Extracelular/metabolismo , Yodoacetatos , Lectinas Tipo C , Masculino , Modelos Animales , Proteoglicanos/metabolismo , Ratas , Ratas Sprague-Dawley , Factores de TiempoRESUMEN
OBJECTIVE: Characterize a model of osteoarthritis (OA) induced by a surgically transecting the medial collateral ligament and meniscus. Evaluate the effectiveness of a matrix metalloproteinase (MMP) inhibitor in this model. METHODS: The medial collateral ligament of the right knee of rats was transected and a single full thickness cut was made through meniscus. Rats were sacrificed at various times after the surgery to assess the severity of gross cartilage damage using an image analyser and microscopically by histology. The effect of an MMP inhibitor in this model was assessed by administering compound twice daily for the 21 days and evaluating gross and histological joint damage at day 21. The in vitro potency of the MMP inhibitor (MMPI) against a panel of human recombinant MMPs was assessed kinetically using a quenched fluorescent substrate. RESULTS: Surgical transection of the medial collateral ligament and meniscus resulted in a time dependent increase in the severity of the cartilage lesion (depth) as measured histologically but only a slight increase in the area of the lesion as assessed grossly by image analysis. Administration of a MMPI orally twice daily (b.i.d.) at 25mg/kg to rats in the meniscal tear model resulted in significant inhibition of cartilage degradation and osteophyte formation (total joint score) of 39+/-7% (mean+/-S.E.M., from four separate experiments). CONCLUSION: These results demonstrate that MMP inhibition is effective in reducing the joint damage that occurs in the meniscal tear model of OA and support a potential therapeutic role for MMP inhibition in the treatment of human OA.
Asunto(s)
Modelos Animales de Enfermedad , Miembro Posterior/patología , Articulaciones/patología , Inhibidores de la Metaloproteinasa de la Matriz , Meniscos Tibiales/cirugía , Osteoartritis/patología , Animales , Ligamentos Colaterales/cirugía , Masculino , Microscopía Electrónica , Ratas , Ratas Endogámicas LewAsunto(s)
Compuestos de Bifenilo/síntesis química , Ácidos Carboxílicos/síntesis química , Inhibidores de la Metaloproteinasa de la Matriz , Inhibidores de Proteasas/síntesis química , Compuestos de Bifenilo/química , Proteínas Sanguíneas/química , Ácidos Carboxílicos/química , Inhibidores de Proteasas/química , Solubilidad , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
Potent and selective inhibition of matrix metalloproteinases was demonstrated for a series of sulfonamide-based hydroxamic acids. The design of the heterocyclic sulfonamides incorporates a six- or seven-member central ring with a P2' substituent that can be modified. Binding interactions of this substituent at the S2' site are believed to contribute to high inhibitory potency against stromelysin, collagenase-3 and gelatinases A and B, and to provide selectivity against collagenase-1 and matrilysin. An X-ray structure of a stromelysin inhibitor complex was obtained to provide insights into the SAR and selectivity trends observed for the series.
Asunto(s)
Compuestos Heterocíclicos con 1 Anillo/farmacología , Inhibidores de la Metaloproteinasa de la Matriz , Sulfonamidas/farmacología , Colagenasas , Cristalografía por Rayos X , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacología , Compuestos Heterocíclicos con 1 Anillo/síntesis química , Concentración 50 Inhibidora , Sustancias Macromoleculares , Metaloproteinasa 13 de la Matriz , Sensibilidad y Especificidad , Relación Estructura-Actividad , Sulfonamidas/síntesis químicaRESUMEN
OBJECTIVE: To determine the effect of matrix metalloproteinase (MMP) inhibitors in mono-iodoacetate-induced arthritis in rats. DESIGN: The ability of compounds to inhibit MMPs in vitro was assessed kinetically using a quenched fluorescent substrate. Rats were injected with iodoacetate intraarticularly in one knee joint and damage to the tibial plateau was evaluated from digitized images captured using an image analyser and by histology. Collagenase and gelatinase activity in cartilage from iodoacetate injected knees were evaluated using(3)H-rat type I collagen and gelatin zymography, respectively. RESULTS: Collagenase and gelatinase activity significantly increased in the knee cartilage of rats injected with iodoacetate with peak activity by day 7. Three MMP inhibitors were examined for their efficacy in the rat iodoacetate-induced arthritis model. Significant (P< 0.05) inhibition of cartilage damage was observed in animals treated orally with 35 mg/kg b.i.d. of the three different MMP inhibitors. Inhibition of cartilage damage by the MMP inhibitors ranged from 36-42%. CONCLUSION: MMP inhibitors are partially protective against cartilage and subchondral bone damage induced by iodoacetate. These results support an important role for MMPs in mediating the joint damage in this model of arthritis.
Asunto(s)
Inhibidores Enzimáticos/uso terapéutico , Inhibidores de la Metaloproteinasa de la Matriz , Osteoartritis/tratamiento farmacológico , Animales , Colagenasas/metabolismo , Electroforesis en Gel de Poliacrilamida/métodos , Gelatinasas/metabolismo , Procesamiento de Imagen Asistido por Computador/métodos , Inyecciones Intraarticulares , Yodoacetatos/administración & dosificación , Yodoacetatos/efectos adversos , Masculino , Osteoartritis/inducido químicamente , Osteoartritis/patología , Ratas , Ratas Sprague-Dawley , Regulación hacia ArribaRESUMEN
A new generation of cyclic matrix metalloproteinase (MMP) inhibitors derived from dl-piperazinecarboxylic acid has been described. The design involves: incorporation of hydroxamic acid as the bidentate chelating agent for catalytic Zn(2+), placement of a sulfonamide group at the 1N-position of the piperazine ring to fill the S1' pocket of the enzyme, and finally attachment of diverse functional groups at the 4N-position to optimize potency and peroral absorption. A unique combination of all three elements produced inhibitor 20 with high affinity for MMPs 1, 3, 9, and 13 (24, 18, 1.9, and 1.3 nM, respectively). X-ray crystallography data obtained for MMP-3 cocrystallized with 20 gave detailed information on key binding interactions defining an overall scaffold geometry for piperazine-based MMP inhibitors.
Asunto(s)
Metaloendopeptidasas/antagonistas & inhibidores , Piperazinas/síntesis química , Inhibidores de Proteasas/síntesis química , Sulfonamidas/síntesis química , Animales , Cartílago/citología , Cartílago/efectos de los fármacos , Bovinos , Células Cultivadas , Cristalografía por Rayos X , Diseño de Fármacos , Modelos Moleculares , Piperazinas/química , Piperazinas/farmacología , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Proteínas Recombinantes/antagonistas & inhibidores , Estereoisomerismo , Relación Estructura-Actividad , Sulfonamidas/química , Sulfonamidas/farmacologíaRESUMEN
A series of hydroxamates was prepared from an aminoproline scaffold and tested for efficacy as matrix metalloproteinase (MMP) inhibitors. Detailed SAR for the series is reported for five enzymes within the MMP family, and a number of inhibitors, such as compound 47, display broad-spectrum activity with sub-nanomolar potency for some enzymes. Modifications of the P1' portion of the molecule played a key role in affecting both potency and selectivity within the MMP family. Longer-chain aliphatic substituents in this region of the molecule tended to increase potency for MMP-3 and decrease potency for MMP-1, as exemplified by compounds 48-50, while aromatic substituents, as in compound 52, generated broad-spectrum inhibition. The data is rationalized based upon X-ray crystal data which is also presented. While the in vitro peroral absorption seemed to be less predictable, it tended to decrease with longer and more hydrophilic substituents. Finally, a rat model of osteoarthritis was used to evaluate the efficacy of these compounds, and a direct link was established between their pharmacokinetics and their in vivo efficacy.
Asunto(s)
Ácidos Hidroxámicos/síntesis química , Metaloendopeptidasas/antagonistas & inhibidores , Prolina/análogos & derivados , Prolina/síntesis química , Inhibidores de Proteasas/síntesis química , Animales , Cartílago Articular/patología , Cristalografía por Rayos X , Humanos , Ácidos Hidroxámicos/química , Ácidos Hidroxámicos/farmacología , Yodoacetatos , Masculino , Metaloproteinasa 3 de la Matriz/química , Modelos Moleculares , Osteoartritis de la Rodilla/inducido químicamente , Osteoartritis de la Rodilla/tratamiento farmacológico , Osteoartritis de la Rodilla/patología , Prolina/química , Prolina/farmacología , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Ratas , Ratas Sprague-Dawley , Relación Estructura-ActividadRESUMEN
The synthesis and enzyme inhibition data for a series of thiazine- and thiazepine-based matrix metalloproteinase (MMP) inhibitors are described. The thiazine- and thiazepine-based inhibitors were discovered by optimization of hetererocyclic sulfonamide-based inhibitors. The most potent series of inhibitors was obtained by modification of the amino acid D-penicillamine. This amino acid provides a gem-dimethyl group on the thiazine or thiazepine ring which has a dramatic effect on the in vitro potency of this series. In particular, the sulfide 4a and the sulfone 5a were potent, broad-spectrum inhibitors of the MMPs with IC(50)'s against MMP-1 of 0.8 and 1.9 nM, respectively. The binding mode of this novel thiazepine-based series of MMP inhibitors was established based on X-ray crystallography of the complex of stromelysin and 4a.
Asunto(s)
Óxidos S-Cíclicos/síntesis química , Inhibidores Enzimáticos/síntesis química , Metaloendopeptidasas/antagonistas & inhibidores , Tiazepinas/síntesis química , Tiazinas/síntesis química , Cristalografía por Rayos X , Óxidos S-Cíclicos/química , Diseño de Fármacos , Inhibidores Enzimáticos/química , Modelos Moleculares , Relación Estructura-Actividad , Tiazepinas/química , Tiazinas/químicaRESUMEN
Since their inception during the eighties, MMP inhibitors (MMPIs) have gone through several cycles of metamorphosis. The design of early MMPIs was based on the cleavage site of peptide substrates. The second generation contained a substituted succinate scaffold (e.g., marimastat) coupled to a modified amino acid residue. The lower molecular weight analogs with multiple substitution possibilities produced a series of MMP inhibitors with varying degrees of selectivity for various MMPs. The introduction of sulfonamides in the midnineties added a new dimension to this field. The simplicity of synthesis coupled with high potency (e.g., CGS-27023A, AG-3340) produced a number of clinical candidates. This review highlights some of the key features that contributed to the discovery of this novel series of MMP inhibitors.
Asunto(s)
Metaloendopeptidasas/antagonistas & inhibidores , Inhibidores de Proteasas/síntesis química , Caprolactama/síntesis química , Caprolactama/química , Caprolactama/farmacología , Diseño de Fármacos , Matriz Extracelular/enzimología , Metaloendopeptidasas/química , Ácidos Fosfínicos/síntesis química , Ácidos Fosfínicos/química , Ácidos Fosfínicos/farmacología , Piperazinas/síntesis química , Piperazinas/química , Piperazinas/farmacología , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacologíaRESUMEN
OBJECTIVES: Chondrocytic matrix metalloproteinases (MMPs) are believed to be important in osteoarthritic cartilage degradation. The cartilage lesion of osteoarthritis (OA) is focal and often progressive. During its development chondrocytes differentially up and down regulate production of mRNA for individual MMPs. This observation has potential implications for understanding the disease processes that lead to progressive cartilage loss in OA and designing appropriate targeted treatment. The complex regulation of MMP mediated effects means there is a pressing need to establish whether visualisation of MMP mRNA or protein equates to enzyme activity. The technique of in situ zymography (ISZ) offers a way of examining diseased human tissue for in vivo production of an excess of degrading enzyme over inhibitor. The primary objective of this study was to assess, and if positive follow, collagen II degrading activity in cartilage during development of the OA lesion. A secondary objective was to assess whether there was any correlation between sites of collagen II degrading activity and expression of the collagenase (MMP-13), recently implicated in type II collagen degredation in this lesion. METHODS: Biopsied human normal and osteoarthritic cartilage, showing various degrees of damage, was examined by in situ zymography, with and without enzyme inhibitors, to establish sites of type II collagenase activity. Paired samples were probed for MMP-13 mRNA using 35S-labelled oligonucleotide probes. Comparative analyses were performed. RESULTS: In situ zymography showed collagen II degrading activity over chondrocytes only in osteoarthritic cartilage. Distribution and amount varied with the extent of cartilage damage and position of chondrocytes, being greatest in deep cartilage and in cartilage lesions where fissuring was occurring. The enzyme causing the degradation behaved as a matrix metalloproteinase. MMP-13 mRNA expression codistributed with the type II collagenase activity. CONCLUSION: In OA, chondrocytes can degrade type II collagen. The type II collagen degrading activity varies in site and amount as the cartilage lesion progresses and throughout codistributes with MMP-13 mRNA expression.
Asunto(s)
Cartílago Articular/enzimología , Colágeno/metabolismo , Colagenasas/metabolismo , Adulto , Anciano , Pruebas Enzimáticas Clínicas , Colágeno/análisis , Electroforesis en Gel de Poliacrilamida , Femenino , Humanos , Hibridación in Situ , Masculino , Metaloproteinasa 13 de la Matriz , Persona de Mediana Edad , Osteoartritis/enzimología , ARN Mensajero/análisisRESUMEN
A new series of hydroxamic acid-based matrix metalloproteinase (MMP) inhibitors containing a unique phosphinamide motif derived from D-amino acid was designed, synthesized, and tested for enzyme inhibition. Compounds with an R configuration at phosphorus were found to be potent MMP inhibitors while molecules with the S configuration were almost inactive. Structure-activity relationship studies of the series led to the discovery of the potent inhibitor 16 with IC50 = 20.5 nM and 24.4 nM against fibroblast collagenase (MMP-1) and stromelysin (MMP-3), respectively. The binding mode of this novel phosphinamide-based series of MMP inhibitors was established based on X-ray crystallography of the complex of stromelysin and 16.
Asunto(s)
Ácidos Hidroxámicos/síntesis química , Metaloendopeptidasas/antagonistas & inhibidores , Compuestos Organofosforados/síntesis química , Inhibidores de Proteasas/síntesis química , Sitios de Unión , Cristalografía por Rayos X , Diseño de Fármacos , Humanos , Ácidos Hidroxámicos/química , Ácidos Hidroxámicos/metabolismo , Ácidos Hidroxámicos/farmacología , Metaloproteinasa 1 de la Matriz , Metaloproteinasa 13 de la Matriz , Metaloproteinasa 3 de la Matriz/metabolismo , Metaloproteinasa 7 de la Matriz , Metaloproteinasa 9 de la Matriz , Inhibidores de la Metaloproteinasa de la Matriz , Modelos Moleculares , Compuestos Organofosforados/química , Compuestos Organofosforados/metabolismo , Compuestos Organofosforados/farmacología , Inhibidores de Proteasas/química , Inhibidores de Proteasas/metabolismo , Inhibidores de Proteasas/farmacología , Proteínas Recombinantes/antagonistas & inhibidores , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
The synthesis and structure-activity relationship (SAR) studies of a series of proline-based matrix metalloproteinase inhibitors are described. The data reveal a remarkable potency enhancement in those compounds that contain an sp(2) center at the C-4 carbon of the ring relative to similar, saturated compounds. This effect was noted in compounds that contained a functionalized oxime moiety or an exomethylene at C-4, and the potencies were typically <10 nM for MMP-3 and <100 nM for MMP-1. Comparisons were then made against compounds with similar functionality where the C-4 carbon was reduced to sp(3) hybridization and the effect was typically an order of magnitude loss in potency. A comparison of compounds 14 and 34 exemplifies this observation. An X-ray structure was obtained for a stromelysin-inhibitor complex which provided insights into the SAR and selectivity trends observed within the series. In vitro intestinal permeability data for many compounds was also accumulated.
Asunto(s)
Inhibidores de la Metaloproteinasa de la Matriz , Prolina/química , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Animales , Íleon/efectos de los fármacos , Íleon/metabolismo , Técnicas In Vitro , Absorción Intestinal , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Estructura Molecular , Inhibidores de Proteasas/síntesis química , Ratas , Relación Estructura-ActividadAsunto(s)
Metaloendopeptidasas/antagonistas & inhibidores , Piperazinas/síntesis química , Cristalografía por Rayos X , Metaloproteinasa 1 de la Matriz , Metaloproteinasa 3 de la Matriz/metabolismo , Metaloproteinasa 7 de la Matriz , Metaloproteinasa 9 de la Matriz , Inhibidores de la Metaloproteinasa de la Matriz , Metaloendopeptidasas/metabolismo , Modelos Moleculares , Conformación Molecular , Piperazinas/química , Piperazinas/metabolismo , Piperazinas/farmacología , Inhibidores de Proteasas/síntesis química , Inhibidores de Proteasas/química , Inhibidores de Proteasas/metabolismo , Inhibidores de Proteasas/farmacología , Unión Proteica , Relación Estructura-ActividadRESUMEN
Based on previous in vivo and in situ studies showing that tetracyclines possess antidegenerative effects on cartilage in conjunction with a reduced proteoglycan (PG) loss from the extracellular matrix, we investigated the effects of doxycycline, minocycline and tetracycline on the degradation and biosynthesis of PGs by bovine articular cartilage explants, both in vitro and in situ. Doxycycline, minocycline and tetracycline dose dependently, although weakly, inhibited PG degrading matrix metalloproteinases (MMPs) in vitro, when tested at concentrations ranging from 1 to 100 microM. Ro 31-4724 proved to be a potent inhibitor of MMP proteoglycanases (IC50 value 1.5 nM). Only at a concentration of 100 microM did doxycycline and minocycline significantly inhibit the interleukin-1 (IL-1)-induced augmentation of PG loss from cartilage explants into the nutrient media. The tetracyclines did not modulate the IL-1-mediated reduced aggregability of PGs, whereas 10 microM Ro 31-4724 partially restored the aggregability of PGs ex vivo. Tetracycline even at this high concentration was ineffective. Compared to the effects of the MMP inhibitor Ro 31-4724, treatment with tetracyclines at therapeutic serum levels of 1 or 10 microM was minimal, with little or no effect on cartilage proteoglycanases and PG biosynthesis. In our experiments, tetracyclines and Ro 31-4724 at doses evaluated had no cytotoxic effects on chondrocytes.
Asunto(s)
Antibacterianos/farmacología , Cartílago Articular/efectos de los fármacos , Cartílago Articular/enzimología , Interleucina-1/farmacología , Metaloendopeptidasas/efectos de los fármacos , Metaloendopeptidasas/metabolismo , Proteoglicanos/metabolismo , Animales , Cartílago Articular/metabolismo , Bovinos , Supervivencia Celular/efectos de los fármacos , Técnicas de Cultivo , Doxiciclina/farmacología , Interacciones Farmacológicas , Minociclina/farmacología , Proteoglicanos/biosíntesis , Tetraciclina/farmacologíaRESUMEN
A novel series of conformationally constrained matrix metalloprotease inhibitors was identified. The potencies observed for these inhibitors were highly dependent upon the substitution pattern on the caprolactam ring as well as the succinate moiety.
Asunto(s)
Caprolactama/análogos & derivados , Caprolactama/síntesis química , Metaloendopeptidasas/antagonistas & inhibidores , Inhibidores de Proteasas/química , Inhibidores de Proteasas/síntesis química , Caprolactama/química , Caprolactama/farmacología , Colagenasas/química , Diseño de Fármacos , Indicadores y Reactivos , Cinética , Metaloproteinasa 1 de la Matriz , Metaloproteinasa 3 de la Matriz/química , Inhibidores de la Metaloproteinasa de la Matriz , Modelos Moleculares , Conformación Molecular , Estructura Molecular , Inhibidores de Proteasas/farmacología , Conformación Proteica , Relación Estructura-Actividad , Succinatos/síntesis química , Succinatos/química , Succinatos/farmacologíaRESUMEN
Gait analysis has been undertaken in a rat model of osteoarthrosis, induced by intra-articular injection of sodium iodoacetate into the left knee. Two weeks after injection, no disturbances were recorded to the velocity of locomotion, the stride length nor the stride, stance, or swing times. However, clear and consistent reductions in the peak vertical load bearing (Pz) by the affected limb were observed of 22-29% relative to the other limbs, with the right forelimb taking the major share of extra load. This redistribution fitted well with the gait pattern of the rat, allowing Pz redistribution with minimum gait disturbance, and was still present 6 weeks later. These results are discussed in the context of the possible load sensitivity of the damage process to the gait pattern of the rat.
Asunto(s)
Modelos Animales de Enfermedad , Marcha/fisiología , Osteoartritis/fisiopatología , Animales , Marcha/efectos de los fármacos , Inyecciones Intraarticulares , Yodoacetatos , Ácido Yodoacético , Articulación de la Rodilla/efectos de los fármacos , Articulación de la Rodilla/fisiopatología , Masculino , Osteoartritis/inducido químicamente , Ratas , Ratas WistarRESUMEN
Peptidyl fluoromethyl ketones (PFMK) are irreversible inhibitors of cathepsin B, a cysteine proteinase thought to be involved in the degradation of cartilage. It has been speculated that PFMK inhibitors may metabolize in rodents to form fluoroacetate (FAC), an extremely toxic poison. A highly selective and sensitive separation and detection scheme was developed to measure trace levels of FAC in rat tissues following PFMK dosing. The procedure consisted of extracting FAC from tissue and spiking the extract with [18O]2-fluoroacetate (18O-FAC) as an internal standard. FAC and 18O-FAC were further isolated from matrix components using ion-exchange, solid-phase extraction. The pentafluorobenzyl esters of FAC and 18O-FAC were formed to facilitate the chromatographic separation. Two-dimensional gas chromatography coupled with selected-ion-monitoring detection provided the final measurement. The assay had a limit of detection of 2 ng FAC per g tissue, and was capable of accurately quantitating as little as 10 ng FAC per g tissue with a S/N ratio of 40:1. Linearity was established over two orders of magnitude, from 2-500 ng ml-1, with 5 microliters injected on-column. The method was used to demonstrate that FAC was formed in rats following dosing with Z-Phe-Ala-CH2-F, a PFMK cathepsin enzyme inhibitor.
Asunto(s)
Inhibidores de Cisteína Proteinasa/farmacocinética , Dipéptidos/farmacocinética , Fluoroacetatos/análisis , Cetonas/farmacocinética , Rodenticidas/análisis , Animales , Calibración , Fluoroacetatos/metabolismo , Cromatografía de Gases y Espectrometría de Masas , Hígado/química , Hígado/metabolismo , Ratas , Rodenticidas/metabolismoRESUMEN
Extracellular concentrations of morphine from the dorsal spinal cord, the periaqueductal gray (PAG) including the dorsal raphé, and the lateral hypothalamus were measured by microdialysis in awake rats after intraperitoneal (i.p.) administration of 2.5, 5.0 and 10 mg/kg morphine. Morphine concentrations in all areas showed similar time courses: morphine was detected in the first dialysate sample (13-15 min) and maximal concentrations were reached at 45 min after injection. When in vivo recoveries of morphine from the spinal cord and brain areas were taken into account, no significant differences between morphine concentrations in the various areas were found. The relationship between extracellular morphine concentrations and morphine-induced analgesic behavior was investigated by simultaneously measuring morphine in the dialysate and its analgesic effect in the paw-withdrawal and tail-flick tests. In all areas sampled, the extracellular concentrations of morphine at different times after i.p. injection, significantly correlated with the magnitude of behavioral analgesia assessed by either test. The highest correlation was obtained between extracellular concentrations of morphine in the spinal cord and PAG and behavioral analgesia assessed in the paw-withdrawal test. Our data indicate that, after systemic injection, morphine is evenly distributed throughout the spinal cord and brain including potential anatomical sites of morphine's analgesic action. We estimate that the minimal extracellular morphine concentration in spinal cord that is required to produced a significant increase in nociceptive threshold is approximately 100 pg/25 microl, which corresponds to a tissue concentration of about 100 mg/g of morphine.
Asunto(s)
Analgesia , Hipotálamo/efectos de los fármacos , Morfina/farmacología , Sustancia Gris Periacueductal/efectos de los fármacos , Médula Espinal/efectos de los fármacos , Animales , Conducta Animal/efectos de los fármacos , Química Encefálica/efectos de los fármacos , Estado de Conciencia , Relación Dosis-Respuesta a Droga , Ácido Homovanílico/análisis , Ácido Hidroxiindolacético/análisis , Hipotálamo/química , Masculino , Microdiálisis , Sustancia Gris Periacueductal/química , Ratas , Ratas Sprague-Dawley , Serotonina/análisis , Médula Espinal/químicaRESUMEN
Guanine nucleotide-binding regulatory protein stimulation of adenylyl cyclase has been shown to be an important second messenger system for many processes, including mechanical hyperalgesia. Recently, interactions between guanine nucleotide-binding regulatory protein subunits and adenylyl cyclase affecting the level of cyclic adenosine 3',5'-monophosphate accumulation have been demonstrated. In this study we evaluated such an interaction by measuring paw-withdrawal thresholds to mechanical stimuli in Sprague-Dawley rats in the presence of two direct-acting hyperalgesic agents, prostaglandin E2 and the adenosine A2-agonist, CGS21680. The effects of two agents expected to liberate inhibitory guanine nucleotide-binding regulatory protein subunits were also studied: [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin (a mu-opioid receptor agonist) and N6-cyclopentyladenosine (an A1-adenosine agonist). Injection of [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin immediately before prostaglandin E2 or CGS21680 significantly attenuated the hyperalgesia subsequently induced by these agents, i.e. the sensitivity to these hyperalgesic agents was decreased. On the other hand, injection of [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin 5 min after prostaglandin E2 or CGS21680 significantly enhanced the hyperalgesia observed. Injection of the adenosine A1-agonist N6-cyclopentyladenosine immediately before and 5 min after prostaglandin E2 or CGS21680 had a similar effect to [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin. The decrease in sensitivity to prostaglandin E2- and CGS21680-induced hyperalgesia by preadministration of [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin or N6-cyclopentyladenosine and the enhancement by postadministration were all reversed by pertussis toxin, an inhibitor of inhibitory guanine nucleotide-binding regulatory protein, suggesting the involvement of an inhibitory guanine nucleotide-binding regulatory protein.(ABSTRACT TRUNCATED AT 250 WORDS)